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Abstract. Understanding diagnostic tests and examining important fea-
tures of novel coronavirus (COVID-19) infection are essential steps for
controlling the current pandemic of 2020. In this paper, we study the
relationship between clinical diagnosis and analytical features of patient
blood panels from the US, Mexico, and Brazil. Our analysis confirms
that among adults, the risk of severe illness from COVID-19 increases
with pre-existing conditions such as diabetes and immunosuppression.
Although more than eight months into pandemic, more data have be-
come available to indicate that more young adults were getting infected.
In addition, we expand on the definition of COVID-19 test and discuss
sensitivity and specificity measures. As of November 2020, most devel-
oped testing methodologies assume that COVID-19 is a respiratory ill-
ness and only effective for the first few days of the infection. Hence, a
swapping of either mouth, back of throat or nasal cavity is used for detec-
tion of the virus and the load. Recent studies involve not only discussions
of whether it is respiratory or vascular in nature but also question the
airborne nature of this virus. Our machine learning models are specifi-
cally useful for the diagnosis and management of COVID-19 for patients
with symptoms, yet tested negative, i.e., possibly false negatives. In ad-
dition, our models could be useful for treatment of patients who have
been sick for longer than 60 days as whether the virus is still in their
system.
Keywords: Severe acute respiratory syndrome coronavirus 2 (SARS-
CoV-2), Coronavirus disease 2019 (COVID-19), pandemic, global im-
pact, viral infection, clinical symptoms, diagnosis, prevention, machine
learning
1 Introduction
Charted in April 2014, Pandemic Prediction and Forecasting Science and Tech-
nology Working Group (PPFST WG) of the national science and technology
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council was to coordinate Federal initiatives to accelerate the development of out-
break prevention capabilities. In a report published in December 2016, PPFST
WG identified challenges and recommendations for possible pandemics. Among
them data and information sharing were highlighted [1]. However, the US gov-
ernment led by politicians ignored almost all warnings and information included
in this and similar reports. With the new administration, Centers for Disease
Control and Prevention (CDC) staff members inside China were slashed prior to
the coronavirus outbreak down to around 14 from 47 prior to new administration
in 2016 [2].
Finally, in around November-December 2019, clusters of pneumonia cases of
unknown etiology emerged in Wuhan, Hubei Province, China. Deep sequencing
analysis from lower respiratory tract samples indicated a novel coronavirus as
the causative agent, which was named Severe Acute Respiratory Syndrome-
Coronavirus-2 (SARS-CoV-2), and the disease it causes is called coronavirus
disease (COVID-19) [3], [4]. Although SARS-CoV-2 has shown phylogenetic and
clinical similarities with SARS-CoV, the novel coronavirus appears to have a
higher transmissibility and lower-case fatality rates [5]. On 30 January 2020, the
World Health Organization (WHO) declared the COVID-19 outbreak a Public
Health Emergency of International Concern, and on March 11, the epidemic was
upgraded to pandemic [6].
By November 2020, over 50 million confirmed cases have been reported in
more than 200 countries with deaths more than one million deaths with the
USA, Brazil, and India leading the death toll. Specifically, given over 9 million
confirmed cases and close to 250K deaths in the US, the “naive” mortality rate
is approximately 2.5%. Here, the death rate is calculated simply applying the
formula based on the total number of deaths divided by the total number of
cumulative confirmed cases. However, as the performance of data collection pro-
cesses has not been established and studied, a different method is applied to
obtain a more accurate estimate of the mortality rate [7]. Recent study seems
to challenge such calculation by asserting that “Considering that a large num-
ber of cases are asymptomatic (or present with very mild symptoms) and that
testing has not been performed on the entire population, only a fraction of the
SARS-CoV-2 infected population is detected, confirmed through a laboratory
test, and officially reported as a COVID-19 case. The number of actual cases
is therefore estimated to be at several multiples above the number of reported
cases. The number of deaths also tends to be underestimated, as some patients
are not hospitalized and not tested” [5].
Among metrics to report the severity of pandemic are excess mortality rate,
instantaneous death rate and infection rate per 100K or million. The World
Health Organization define “excess mortality” as: “Mortality above what would
be expected based on the non-crisis mortality rate in the population of interest.
Excess mortality is thus mortality that is attributable to the crisis conditions.
It can be expressed as a rate (the difference between observed and non-crisis
mortality rates), or as a total number of excess deaths.” As of October 2020, the
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CDC published estimated excess mortality death for the US as close to 300K as
the official count was little over 200K.
With the technical advances in instantaneous data propagation, it has been
an easier undertaking to report infections and deaths in per 100K or million.
Moreover, given the contagious nature of this virus, the infection rate is pro-
posed to be somewhat correlated with the population density in countries where
there were no serious attempts to control the spread. We assume data quality to
be acceptable from these countries. Therefore, a naive approach for calculating
rate is to take density into account for better comparison of countries/states.
Although refinement by urban areas in order to adjust metrics could be done at
the lowest level and then aggregate metrics to countries, we will just demonstrate
this idea with the population density as weighing mechanism in the calculation.
Fig. 1. Charts of total number of infected cases (first y-axis in blue bars) and total
number of deaths (second y-axis in orange) ranked by country/state (as of October 30,
2020).
Figure 1 and figure 2 compares unweighted and weighted estimates of total
number of infections per million and deaths per million respectively as of October
30, 2020. Several factors were used to weed out suspect countries such as a simple
outlier test on infection rate and death rate to population size and density. Thus,
14 countries worldwide and 6 worst affected states in the United States were
selected. Detailed statistics in this figure are presented in table 1 and table 2.
3
Tanaydin et al.: SARS-CoV-2 Pandemic Analytical Overview with Machine Learning Predictability
Published by SMU Scholar, 2020
Fig. 2. Charts of total number of infected cases (first y-axis in blue bars) and total
number of deaths (second y-axis in orange) weighted and ranked by country/state (as
of October 30, 2020).
Table 1 contains data sorted by number of cases per million. The United
States leads the world in the number of total number of cases and total number
of deaths with more than 9 million infected cases and over 220K deaths followed
by Brazil, France, Spain, Argentina, Colombia, and United Kingdom. These
values have been the most popular metrics used to gauge severity of pandemic
in government and media reporting during the first few months of pandemic.
Another metric that is more reflective of true comparison is total number of
cases in millions. In this case, state of Florida ranks first with 39,475 infections
per million followed by state of Georgia, Belgium, State of Texas, and State
of Illinois. In contrast to other very heavily populated countries and states, for
instance, South Korea managed the pandemic exceptionally well with about
15% of the US population yet accounting for 0.2% of total deaths of the US.
That is, without taking into consideration of density, had the pandemic been
managed, the expected number of deaths in the US would have been little over
3K comparing to over 220K as of October 30.
Data sorted by weighted number of cases per million using population density
are presented in table 2. The United States ranks first followed by United King-
dom, France, Belgium, Brazil, Italy, and Germany. Several European countries
are ranked high, indicating a new fresh spike in COVID-19 cases over the last
several weeks in Europe although they demonstrated more success controlling
the outbreak early spring 2020. As of fall 2020, a second wave of coronavirus
4
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Table 1. 20 selected regions ranked by number of cases per million of population as
of October 30, 2020.









1 State of Florida 800,216 39,475 16,720 825
2 State of Georgia 358,225 35,069 7,955 779
3 Belgium 392,258 33,846 11,308 976
4 State of Texas 924,036 33,639 18,384 669
5 State of Illinois 408,648 32,279 9,994 789
6 United States 9,029,959 27,281 229,585 694
7 Peru 897,594 27,223 34,362 1,042
8 Chile 508,571 26,604 14,158 741
9 Brazil 5,494,376 25,849 158,969 748
10 State of New York 505,431 25,532 33,451 1,690
11 Spain 1,185,678 25,360 35,878 767
12 Argentina 1,143,800 25,308 30,792 681
13 State of California 927,281 23,688 17,614 450
14 France 1,377,255 21,100 36,605 561
15 Colombia 1,048,055 20,597 31,421 618
16 United Kingdom 992,874 14,626 46,319 682
17 Sweden 124,355 12,313 5,938 588
18 Italy 647,674 10,712 38,321 634
19 Germany 517,720 6,179 10,391 124
20 South Korea 26,385 515 463 9
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pandemic has emerged distinctly amid economic and social diseaster left from
the first wave, especially in Europe. Table 3 and table 4 present the adjusted
rankings based on unweighted and weighted estimates of total number of cases
per million respectively as of November 20, 2020. Compared with table 1 and
table 2, the pandemic in the US is still growing out of control. The US state,
Texas has surpassed California with the highest number of positive COVID-19
infections. Meanwhile, during the US presidential election campaigns, activities
coupled with disinformation regarding mask wearing and other preventing mea-
sures accelerated the spread of the pandemic exponentially. In Europe, for exam-
ple, the number of infections in Italy doubled in 20 days of November; in Spain,
France, United Kingdom, and Germany, the number of new infections in each
country exceeded alarming 300K. Consequently, government agencies in many
countries were trying to enact stricter rules to prevent the spread of COVID-19.
The Federal Government of Belgium declared to close bars and restaurants, and
French government has imposed a strict 9 pm to 6 am curfew as the UK locked
down the country for the entire month of November 2020 [8]. More countries
started asking their citizens to continue to be vigilant.
Table 2. 20 selected regions ranked by weighted number of cases per million of popu-
lation as of October 30, 2020.












1 United States 27,281 2,494 694 63
2 United Kingdom 14,626 2,170 682 101
3 France 21,100 1,274 561 34
4 Belgium 33,846 1,164 976 34
5 Brazil 25,849 1,072 748 31
6 Italy 10,712 1,016 634 60
7 Germany 6,179 950 124 19
8 State of Florida 39,475 913 825 19
9 Spain 25,360 857 767 26
10 State of California 23,688 703 450 13
11 State of New York 25,532 641 1,690 42
12 Colombia 20,597 365 618 11
13 State of Texas 33,639 293 669 6
14 State of Illinois 32,279 284 789 7
15 State of Georgia 35,069 191 779 4
16 Peru 27,223 180 1,042 7
17 Argentina 25,308 145 681 4
18 South Korea 515 106 9 2
19 Chile 26,604 101 741 3
20 Sweden 12,313 22 588 1
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Table 3. 20 selected regions ranked by number of cases per million of population as
of November 20, 2020.









1 State of Illinois 634,395 50,111 11,795 932
2 Belgium 550,264 47,479 15,196 1,311
3 State of Florida 923,418 45,553 17,889 882
4 State of Georgia 440,595 43,133 9,142 895
5 State of Texas 1,107,775 40,328 20,583 749
6 United States 11,859,825 35,830 253,943 767
7 Spain 1,556,730 33,296 42,619 912
8 France 2,159,978 33,091 48,339 741
9 Argentina 1,349,434 29,858 36,532 808
10 State of New York 579,382 29,268 34,234 1,729
11 Peru 943,917 28,628 35,446 1,075
12 Brazil 5,981,767 28,142 168,061 791
13 Chile 537,585 28,122 15,003 785
14 State of California 1,083,797 27,687 18,579 475
15 Colombia 1,233,444 24,241 34,929 686
16 Italy 1,345,767 22,258 48,569 803
17 United Kingdom 1,477,214 21,760 54,381 801
18 Sweden 208,295 20,625 6,406 634
19 Germany 901,526 10,760 13,773 164
20 South Korea 30,017 585 501 10
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Table 4. 20 selected regions ranked by weighted number of cases per million of popu-
lation as of November 20, 2020.












1 United States 35,830 3,275 767 70
2 United Kingdom 21,760 3,229 801 119
3 Italy 22,258 2,111 803 76
4 France 33,091 1,998 741 45
5 Germany 10,760 1,654 164 25
6 Belgium 47,479 1,633 1,311 45
7 Brazil 28,142 1,167 791 33
8 Spain 33,296 1,125 912 31
9 State of Florida 45,553 1,054 882 20
10 State of California 27,687 821 475 14
11 State of New York 29,268 735 1,729 43
12 State of Illinois 50,111 441 932 8
13 Colombia 24,241 430 686 12
14 State of Texas 40,328 351 749 7
15 State of Georgia 43,133 235 895 5
16 Peru 28,628 189 1,075 7
17 Argentina 29,858 172 808 5
18 South Korea 585 120 10 2
19 Chile 28,122 106 785 3
20 Sweden 20,625 37 634 1
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According to a recent research, coronaviruses are enveloped, positive single-
stranded RNA viruses widely distributed in humans and animals worldwide [9].
Although most human coronavirus infections are mild, major outbreaks of two
beta coronaviruses, severe acute respiratory syndrome coronavirus (SARS-CoV)
in 2002-2003 and Middle East respiratory syndrome coronavirus (MERS-CoV) in
2012, have caused deadly pneumonia, with mortality rates of 10% for SARS-CoV
and 36% for MERS-CoV [10].
Early on the virus is thought to spread from person-to-person via respiratory
droplets. “Droplets suspended in the air are called an aerosol. Droplets that are
large can remain in the air for seconds to minutes before falling to the ground.
Smaller droplets stay in the air longer - minutes to even hours. Researchers found
that the COVID-19 virus stayed viable in the air for three hours. The researchers
estimate that in most real-world situations, the virus would remain suspended
in the air for about 30 minutes, before settling onto surfaces. This is similar to
what was found for SARS and MERS, which some researchers consider likely to
be spread via airborne transmission.” [11] These droplets can land in the noses,
mouths, or eyes. Some studies also suggest that disease may be transmitted as
airborne as well as by people who are not showing symptoms (asymptomatic).
Currently, there are no scientific studies suggesting with certainty that whether
every exposure to an environment which SARS-CoV-2 present results in COVID-
19 infection. As there is no reliable way to prevent getting infected for certain,
avoiding gatherings and staying home are the most effective ways to prevent an
infection while taking precautions such as social distancing and mask wearing.
To be more specific, WHO indicated several possible transmission patterns of
COVID-19, including ”contact, droplet, airborne, fomite, fecal-oral, blood-borne,
mother-to-child, and animal-to-human transmission. Infection with SARS-CoV-
2 primarily causes respiratory illness ranging from mild disease to severe disease
and death, and some people infected with the virus never develop symptoms.
Recent publications are also indicative of infection being vascular kind.” [12]
“As mentioned above, airborne transmission that is caused by the dissemina-
tion of droplet nuclei (aerosols) that remain infectious when suspended in air over
long distances and time. Airborne transmission of SARS-CoV-2 can occur dur-
ing medical procedures that generate aerosols (“aerosol generating procedures”).
WHO, together with the scientific community, has been actively discussing and
evaluating whether SARS-CoV-2 may also spread through aerosols in the ab-
sence of aerosol generating procedures, particularly in indoor settings with poor
ventilation.” [12]
“Respiratory secretions or droplets expelled by infected individuals can con-
taminate surfaces and objects, creating fomites (contaminated surfaces). Viable
SARS-CoV-2 virus and/or RNA detected by RT-PCR can be found on those
surfaces for periods ranging from hours to days, depending on the ambient en-
vironment (including temperature and humidity) and the type of surface, in
particular at high concentration in health care facilities where COVID-19 pa-
tients were being treated.” [12]
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“Other modes of transmission of COVID-19 is also considered. SARS-CoV-2
RNA has also been detected in other biological samples, including the urine and
feces of some patients. One study found viable SARS-CoV-2 in the urine of one
patient.” [12]
Among the factors that affect sensitivity are measurement system factors,
i.e., test kit, collection method, location, operator, shipment, lab, and whether
the virus is present in the respiratory system of nasal cavity or mouth at the
time of sampling. The CDC recommends use of nasopharyngeal (NP) swabs for
molecular testing because in most patients, the nasopharynx, or the space above
the soft palate at the back of the nose, appears to have the highest concentration
of virus. NP swab samples are technically challenging to obtain, and a suboptimal
collection may reduce test sensitivity and increase the likelihood of obtaining a
false-negative result in a patient with the virus.
Testing a swab from the oropharynx or nose is also likely to reduce sensitivity
[13], [14]. Other sample types such as saliva or blood likely result in even lower
sensitivity [15]. For patients with pneumonia, on the other hand, specimens such
as bronchoalveolar lavage collected from the lower respiratory tract may have
sensitivity equal to or better than an NP swab, although collection of these types
of samples increases the biosafety risk to healthcare workers [16].
The timing of sample collection is also important because the amount of virus
present in the nasopharynx varies over the course of infection. Ideally, samples
should be collected near the time of symptom onset to achieve the highest test
sensitivity [17]. Patients who are infected but not yet symptomatic may have
false-negative test results, as may those whose symptoms are waning [18].
Furthermore, we would like to define for our study purposes, two groups of
COVID-19 infected patients:
1. Asymptomatic COVID-19 patients
2. Symptomatic COVID-19 patients:
2a. Patients who exhibit a subset of symptoms who are self-isolated and re-
cover fully in two to six weeks
2b. Acute COVID-19 patients: heavy symptomatic people who are hospital-
ized
2c. Chronic COVID 19 patients who have symptoms for longer than a month
In this study, our interest is group 2, specifically the subgroups 2a and 2b. We
analyzed the US California dataset in addition to Mexico diagnostic data that
the relationship between medical diseases such as diabetes or immunosuppres-
sion and COVID-19 is verified. Finally, based on the results of laboratory tests
collected for suspected COVID-19 cases during visits to the emergency room
in a Brazilian hospital, we demonstrated that it is possible to predict the test
result for SARS-CoV-2 positive at 94.87% accuracy. Results suggested that low
levels of leukocytes, platelets and eosinophils as well as high levels of C-reactive
protein and age are strong indicators of severity of COVID-19 infection pres-
ence. Besides, as part of improving one’s preparedness of such a case, our study
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findings are aligned with healthy lifestyle guidelines that consist of nutrient rich
foods and exercise.
2 Background
COVID-19 is a new and serious infectious disease. Although it is still not fully
understood, among common symptoms of such infection with this disease are
fever, cough, shortness of breath or difficulty breathing, chills, fatigue, muscle
pain, headache, sore throat, new loss of taste or smell, runny nose, nausea, and
diarrhea [19]. For group 2 as defined above, an infected person might exhibit a
subset of symptoms within 3-7 days of exposure to the virus, but in some cases,
it has taken up to 14 days for symptoms to appear.
Initially, it was thought that infection was spread through contacts with in-
fected people or surface like any other respiratory disease. Seven months into
the pandemic, it is theorized COVID-19 is spread through not just through air-
droplets that are dispersed when an infected person talks, sneezes or coughs but
it is also airborne. The virus can survive from a few hours up to a few days de-
pending on the environmental conditions. It can be spread through close contact
with an infected person or by contact with air droplets in the environment, e.g.,
on a surface. Then, touching the mouth or nose can cause infection. The CDC
made available guidelines on hand hygiene and social distancing [19].
As mentioned above, everyone is at risk for getting COVID-19 if they are ex-
posed to the virus. For most of patients, that is group 2, COVID-19 is experienced
mildly, with minimal flu-like symptoms. Some patients do not show symptoms
(asymptomatic - group1) or only very mild symptoms, more like a common cold.
Moreover, it is not clear so far that what percent of people who are exposed get
sick, in particular, people with medical conditions such as chronic lung disease or
diabetes. The current research published by CDC implies a relationship between
COVID-19 and diabetes among other pre-existing illnesses [20], [21]. Thus, it is
an interest to understand the likelihood of those with a compromised immune
system, especially with diabetes or hypertension that require hospitalization. A
further interest is to identify the characteristics of patients that are indicative of
needing to be admitted to ICU with ventilators and likelihood of their survival.
In the early days of the pandemic, majority of people who were reported
to be infected were older segment of the population, mostly age 65+. It is our
hypothesis that younger people were infected at the same rate or higher in the
beginning of the pandemic, but they were mostly asymptomatic, group 1 with
very few exhibiting severe symptoms. In addition, there are no systematic and
scientific assessment of measurement system whether the virus exists in a per-
son’s body at any time. Most widely available test in the US is the nasal or
throat swap test. Although some studies suggest high accuracy of these tests
under controlled conditions, there is high variability in collection methods, tim-
ing, transportation etc. Among the factors that contribute to false negative rates
are the timing of collection and whether the virus is present at the nasal cavity
or in the respiratory system. Negative test result only indicate that virus is not
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present at the nasal passage at the time of swap. It does not necessarily indicate
non-existence in the lungs or intestines for example. Hence, false-negative test
results are estimated to be in much higher numbers/rate than originally thought.
In spite of possibility of much higher false negative rates, more than six
months into the pandemic, data depicted by figure 3 show more younger adults
being infected than older adults. Although people with stronger immune system
are more resilient to the infection, i.e., mostly younger age of the population, they
are not fully protected from the infection. Data obtained from three different re-
gions: California, New York City, and Texas consistently show this phenomenon
[22], [23], [24].
Fig. 3. Trend lines by Age in California, New York City, and Texas (as of October
29, 2020). Blue and orange lines are used for number of cases/million and number of
deaths/million respectively. Texas data only come from completed case investigations
received by Texas Department of State Health Services.
Thus, there is a distinct possibility that death rate is associated with age
while immune weakness/underlying health problems could be the lurking vari-
ables. The risk of contracting COVID-19 is thought to be confounded with the
underlying medical conditions one might have. Among such mentioned underly-
ing conditions are chronic kidney disease, COPD (chronic obstructive pulmonary
disease), immunocompromised state (weakened immune system) from solid or-
gan transplant, obesity (body mass index [BMI] of 30 or higher), serious heart
conditions such as heart failure, coronary artery disease, or cardiomyopathies,
sickle cell disease, Type 2 diabetes mellitus, etc. [21]
12




The data were sourced from Coronavirus Disease 2019 (COVID-19) Clinical
Data Repository. The dataset includes the clinical characteristics (epi factors,
comorbidities, vitals, clinician-assessed symptoms, patient-reported symptoms)
in addition to radiological and laboratory findings. It does not include treatment
plans, complications, and clinical outcomes, which is collected at inpatient facil-
ities. The data include test results of patients with mild symptoms and asymp-
tomatic patients, but such data do not contain results for patients with severe
symptoms. A patient’s reported age differs from their actual age by a reasonable
randomized amount to protect their privacy [25]. As of October 30, 2020, there
are 11,169 observations and 46 features in total, with 10,854 tested as negative,
and 315 positive. Again, having more than 97% of the cases tested as negative
and not knowing the false-negative rates create difficulty in sensitizing about
measurement system and data it produces. Variables can be generally divided
into three specific groups: demography, qualitative physical exams, and quanti-
tative physical exam variables. Table 5 presents preliminary variable names and
short descriptions.
Table 5. Variables of Interest in the California Data Set.
Variable Description Specification
temperature Body temperature C Normal: 97F (36.1C) to 99F
(37.2C)
age Patient age Range 0 to 100
pulse Heart rate measured as the
number of heart beats per
minute (bpm)
Normal 60 – 100
rr Respiratory rate measured
in breaths per minute
Normal 12-15
Abnormal < 12 or > 15
sats Oxygen saturation mea-
sured as the percentage of
hemoglobin binding sites in
the bloodstream occupied
by oxygen
Oxygen level, or saturation
(SpO2), Normal SpO2 is usu-
ally at least 95%
sys Systolic blood pressure
measured in millimeters of
mercury (mmHg)
Normal: less than 120
Elevated: 120 – 129
Hypertension S1: 130 – 139
Hypertension S2: >= 140
Hypertensive crisis: > 180
Table 5 – Continued on next page
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Table 5 – Continued from previous page
Variable Description Specification
dia Diastolic blood pressure
measured in millimeters of
mercury (mmHg)
Normal: less than 80
Elevated: less than 80
Hypertension S1: 80 – 89
Hypertension S2: >= 90
Hypertensive crisis: > 120
diabetes Patient has diabetes (True, False)
chd Patient has coronary heart (True, False)
htn Patient has hypertension (True, False)
asthma Patient has asthma (True, False)
fatigue Patient is experiencing fa-
tigue
(True, False)
headache Patient is experiencing a
headache
(True, False)
loss of smell Patient is experiencing loss
of smell
(True, False)
loss of taste Patient is experiencing loss
of taste
(True, False)
runny nose Patient has a running nose (True, False)
muscle sore Patient has sore muscles (True, False)
sore throat Patient has a sore throat (True, False)
3.2 Mexico Covid-19 Data
Data were obtained from the official website of the Mexican Ministry of Health
through the Directorate General of Epidemiology. These data are analyzed by
The Institute for Diagnosis and Epidemiological References (Instituto de Di-
agnóstico y Referencia Epidemiológica) [26]. According to such continuously
daily updated data, as of October 30, 2020, there are 2,386,284 observations
and 38 columns with all qualitative features except the numerical feature ‘Age’.
3.3 Brazil Hospital Data
This dataset contains anonymized data from patients seen at the Hospital Is-
raelita Albert Einstein, at São Paulo, Brazil, and who had samples collected
to perform the SARS-CoV-2 RT-PCR and additional laboratory tests during a
visit to the hospital [27]. COVID-19 test results and partial blood panel read-
ings for patients were recorded. The dataset contains 5,644 observations and 111
variables. Although the original data has 5,086 negative and 558 positive cases,
it also contains large amount of missing data. All clinical data are standardized
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to has a mean of zero and a standard deviation of one. Table 6 presents several
variable descriptions, particularly for variables related to complete blood panel.
Table 6. Definitions of blood panel variables for Brazil Hospital Data.
Variable Description
Covid19.Results COVID-19 test results. Positive = 1, Negative = 0
Age Patient age
Platelets Platelets, also called thrombocytes, are a component
of blood whose function (along with the coagulation
factors) is to react to bleeding from blood vessel injury
by clumping, thereby initiating a blood clot [28].
Leukocytes White blood cells (WBCs), also called leukocytes or
leucocytes, are the cells of the immune system that
are involved in protecting the body against both infec-
tious disease and foreign invaders. All white blood cells
are produced and derived from multipotent cells in
the bone marrow known as hematopoietic stem cells.
Leukocytes are found throughout the body, including
the blood and lymphatic system [29].
Eosinophils Eosinophils are a variety of white blood cells and one of
the immune system components responsible for com-
bating multicellular parasites and certain infections in
vertebrates [30]. Along with mast cells and basophils,
they also control mechanisms associated with allergy
and asthma. They are granulocytes that develop dur-
ing hematopoiesis in the bone marrow before migrat-
ing into blood, after which they are terminally differ-
entiated and do not multiply. [31].
Monocytes The term monocyte is used for blood cells of a lin-
eage called monocytes/macrophages or mononuclear
phagocytes. These blood monocytes are bone marrow-
derived leukocytes that are functionally characterized
by the ability to phagocytose, to produce cytokines,
and to present antigen [32].
Lymphocytes Lymphocytes are white blood cells uniform in appear-
ance but varied in function and include T, B, and nat-
ural killer cells. These cells are responsible for anti-
body production, direct cell-mediated killing of virus-
infected and tumor cells, and regulation of the im-
mune response. [33]. Lymphocyte makes up between
18% and 42% of circulating leukocytes [34].
Table 6 – Continued on next page
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Table 6 – Continued from previous page
Variable Description
Basophils Basophils (or Basophilic granulocytes) are a type of
leucocyte that circulates in the blood. They are the
rarest of the granulocytes (the others are neutrophils
and eosinophils), usually representing less than 0.5% of
leucocytes in the peripheral blood of humans or mice.
Basophils can participate in the expression of acute
and chronic and allergic diseases, including anaphy-
laxis, asthma, atopic dermatitis and hay fever [35].
Proteina.C C-reactive protein (CRP) is a phylogenetically highly
conserved plasma protein, with homologs in verte-
brates and many invertebrates, that participates in the
systemic response to inflammation. Its plasma concen-
tration increases during inflammatory states, a char-
acteristic that has long been employed for clinical pur-
poses [36].
Mean.Platelet.Volume The mean platelet volume (MPV) is an important
marker of platelet activity and is associated with car-
diovascular risk factors [37].
Red.Blood.Cells The number of red blood cells
4 Methodology
4.1 California Data
We mainly detected 7 numerical and 25 categorical variables. For numeric vari-
ables such as age and temperature, we used one sided two sample t-test to check
the mean difference for each numerical feature between positive and negative
groups. For categorical variables, percentages for each variables for each level
(negative or positive) were reported to see the proportion difference. Meanwhile,
statistical analysis of comparisons such as one sided two proportion z-test for
several categorical variables related to medical conditions was carried out to test
the difference in proportions.
4.2 Mexico COVID-19 Data
Values of ‘Not applicable’, ‘Not specified’ were considered missing and were
set to ‘Undecided’. Similarly, we applied same statistical methods to analyze
characteristics of several categorical variables in this dataset to compare with
the results obtained from California data. Furthermore, we investigated several
variables such as Obesity, Cardiovascular, and immunosuppression.
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4.3 Brazil Hospital Data
1. Data Cleansing
Missing Values:
All variables with more than 95% values missing were deleted. Most variables
that over 95% are missing represent values correlated with the urinary system
such as urobilinogen or ketone bodies; however, we opted not to analyze these
variables.
Categorical variables:
Each of the 20 categorical variables represents whether a patient has a particu-
lar disease or not. Most of these variables have around 70% missing values such
as Chlamydophila pneumoniae or respiratory syncytial virus. To detect whether
these disease features are correlated with the target variable COVID-19.Results,
a summary of a built contingency table is presented in table 7. Only Coro-
navirusNL63, Coronavirus229E, Rhinovirus/Enterovirus, Influenza B, and In-
fluenza B, rapid test detected 3, 1, 6, 3, 2 cases respectively. We only kept these 5
features and removed all other features. Based on these 5 disease features, feature
engineering was used to create a new binary variable called ‘other disease check’
that records whether a patient has one of the diseases. Then we checked its
correlation with target variable.
Numerical Variables:
A correlation plot based on Pearson’s correlation test is presented in figure 4.
Eosinophils, other disease check, Leukocytes, Monocytes, and Platelets are iden-
tified as the most important variables related to the Covid19.Results response
variable (positive/negative). Covid19.Results is positively correlated with Mono-
cytes. Eosinophils, Leukocytes, and Platelets have negative correlations with
COVID-19 test results (p-value < 0.001). In addition, the variables Hematocrit,
Hemoglobin, Neutrophils, and Mean.Corpus-cular.Hemoglobin are deleted be-
cause of high correlation with each other. One surprising finding is that the vari-
able other disease check has a negative correlation with Covid19.Results (p-value
< 0.001). This is somewhat counterintuitive; however, such result is reasonable
in this dataset since from table 7, we find that only a few cases show that people
with positive cases have a disease. Thus, we might omit the other disease check
variable in the following machine learning procedures.
2. Imputation and Outliers
Hmisc R is one of the most readily available package to impute missing values
by first introducing missing values completely at random [38]. Median was used
to impute these missing values. In addition to imputation, outliers were removed
in all numerical variables. As a result, 593 observations in 19 columns remain
for machine learning analysis.
3. SMOTE technique
Given the data are highly imbalanced towards that negative cases (because of
suspected false negatives), we used Synthetic Minority Oversampling Technique,
17
Tanaydin et al.: SARS-CoV-2 Pandemic Analytical Overview with Machine Learning Predictability
Published by SMU Scholar, 2020
Table 7. Frequency distributions of all 20 disease variables in the Brazil hospital data.
The table also presents frequencies based on the classification of COVID-19 test results.
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Fig. 4. Correlation plot for numerical variables in the Brazil hospital data. Several
variables are chosen to be deleted due to multicollinearity.
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a.k.a. SMOTE [39]. This procedure down-samples the majority class while syn-
thesizing new cases in the minority class. As a result, we ended up with a subset
of original dataset having 581 rows and 17 columns, with 332 negative and 249
positive cases.
4. Statistical methods
The dataset obtained by applying SMOTE was divided into 80% for training
and 20% for testing of models constructed. Thus, 464 observation are in the
training dataset, and 117 are in the testing dataset. Logistic regression, Random
Forest, Support Vector Machines (SVM), and XGBoost were used to predict
whether the patients would be diagnosed as COVID-19 positive or negative based
on the described clinical data.
5 Results
5.1 California Data
Table 8 displays statistical analysis results for numerical features using multi-
ple comparison tests (one sided t-test). Only sys (systolic blood pressure) does
not show significant difference. Interestingly, the mean age of negative cases is
greater than the mean age of positive cases. This contradicts the assumption
that older adults have weaker immune systems which are more likely to be in-
fected. However, because of the ongoing pandemic, more and more young adults
are more likely to be infected due to no strict self-protection or job occupation,
which we have already mentioned in the background part. Furthermore, there
are some outliers in this dataset. It is necessary to consider every case since not
all associations between body symptoms and COVID-19 are established.
A summary percentage table for all categorical features in the California data
is shown in table 9. Percentages for several features increase from the negative to
positive. For example, if a patient has a profession with a high risk of exposure,
there is a higher risk that he/she would be infected. Also, several common early
symptoms such as fever, cough, headache, loss of taste, loss of smell and muscle
sore are highly correlated with COVID-19.
Pairwise proportions of features such as diabetes, htn, cancer, asthma were
also analyzed. Eight disease variables are summarized in table 10 (one sided
proportion z-test). These variables were chosen as the CDC referred them as po-
tentially increased risk factors for severe COVID-19 infection. Most of categorical
features are not significant to detect percentage differences between positive and
negative cases except the proportion of asthma of positive cases smaller than the
that of negative cases and the proportion of smokers of positive cases less than
that of negative cases. These results are contradictory to the previous discover-
ies mentioned in the background part conducted by the CDC that people with
diabetes or hypertension may be at greater risk for developing serious cases of
COVID-19. Possible explanation for this contradictory result is that there may
be false negative cases as the data were collected in the earlier days of pandemic
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Table 8. Summary table of two sample t-test for each numerical variable in the Cali-
fornia data. We test the mean difference for each variable between positive and negative
COVID-19 test groups. P-value, 95% confidence interval, and conclusion for each vari-
able are shown. * denotes significant numerical variable (only systolic blood pressure
(sys) is not significant).
Variable P-value 95% CI Conclusion at α = 0.05
With 95% confidence,
temperature 0.0000* [−∞,−0.1180] the mean temperature of negative
cases is smaller than that of
positive cases.
age 0.0026* [1.2856,+∞] the mean age of negative cases is
greater than that of positive cases.
pulse 0.0000* [−∞,−3.3908] the mean number of heart beats
per minute of negative cases is
smaller than that of positive cases.
sys 0.3524 [−∞, 1.5105] there is not enough evidence that
the mean systolic blood pressure of
negative cases is smaller than that
of positive cases.
dia 0.0148* [−∞,−0.3997] the mean diastolic blood pressure
of negative cases is smaller than
that of positive cases.
rr 0.0000* [−∞,−0.3832] the mean respiratory rate of
negative cases is smaller than that
of positive cases.
sats 0.0019* [0.1377,+∞] the mean oxygen saturation of
negative cases is greater than that
of positive cases.
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Table 9. Percent distributions of all 25 categorical variables in the California data
based on the classification of COVID-19 test results.




high risk exposure occupation 25.71% 18.3%







autoimmune dis 0.32% 0.70%
smoker 2.86% 7.08%
ctab 8.25% 8.93%








loss of smell 13.65% 1.67%
loss of taste 13.33% 1.78%
runny nose 10.16% 8.61%
muscle sore 17.14% 9.51%
sore throat 11.11% 11.84%
fever 17.78% 6.33%
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Table 10. Summary table for two sample proportion tests for eight categorical vari-
ables in the California data. We test the difference of two proportions for each variable
between positive and negative COVID-19 test groups. P-value, 95% confidence inter-
val, and conclusion for each variable are shown. Only two variables shown with * are
significant are asthma and smoking patients.
Variable P-value 95% CI Conclusion at α = 0.05
With 95% confidence,
diabetes 0.1561 [−0.0079, 1.0000] There is not enough evidence to
show that the proportion of
diabetes of positive cases and the
proportion of diabetes of positive
cases are different.
chd 0.1588 [−1.0000, 0.0008] There is not enough evidence to
show that the proportion of
diabetes of positive cases and the
proportion of diabetes of positive
cases are different.
htn 0.4221 [−1.0000, 0.0227] There is not enough evidence to
show that the proportion of
coronary heart disease of positive
cases and the proportion of
coronary heart disease of positive
cases are different.
cancer 0.4902 [−1.0000, 0.0074] There is not enough evidence to
show that the proportion of
cancer of positive cases and the
proportion of cancer of positive
cases are different.
asthma 0.01433∗ [−1.0000,−0.0135] The proportion of asthma of
positive cases is smaller than the
proportion of asthma of negative
cases.
copd 0.3512 [−1.0000, 0.0038] There is not enough evidence to
show that the proportion of
chronic obstructive pulmonary
disease of positive cases and the
proportion of chronic obstructive
pulmonary disease of positive
cases are different.
autoimmune dis 0.3213 [−1.0000, 0.0032] There is not enough evidence to
show that the proportion of
autoimmune disease of positive
cases and the proportion of
autoimmune disease of positive
cases are different.
smoke 0.0026∗ [−1.000,−0.0246] The proportion of smokers of
positive cases is smaller than the
proportion of smokers of negative
cases.
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while many methods were in their infancy. Only 315 positive cases were recorded
in 11,169 observations in total. Additionally, patients who had severe symptoms
were not included in the data. Thus, for people with mild symptoms or even
asymptomatic patients, it is possible that current regular COVID-19 tests may
not accurately attain correct diagnoses. Thus, we may further look at blood
panel markers to better determine the presence of COVID-19.
5.2 Mexico Data
There is vast amount of data from Mexico that we shortly summarize. These data
have six different medical conditions common to the previous dataset. These are
diabetes, Cardiovascular, htn, smoke, asthma, copd. In addition, Immunosup-
pression variable is included only in Mexico data. There are 2,386,284 cases in
total with 891,550 positive, 1,110,937 negative and 383,797 undecided.
Tests of significance for proportion differences of the Mexican variables are
presented in table 11. Comparing to California dataset, the proportion difference
about all other variables are significant in Mexico data.
In the snapshot taken, there are 276,410 with pre-existing condition diabetes
and 2,101,830 without. Quick summary suggests within negative and positive
categories, about the same number of people with diabetes (133,654 in positive
and 102,146 in negative). However, since fewer people tested for positive COVID-
19, there is a higher percentage of patients with diabetes in positive group.
Statistical test also suggests that the proportion of diabetes of positive cases
is greater than the proportion of diabetes of negative cases (p-value < 0.0001).
This is consistent with our previous finding that people with diabetes might be
at an increased risk for severe illness from COVID-19.
It should be also noted that a dramatic increase in the global burden of type
2 diabetes has been observed globally over the past three decades. In addition
to obesity, age is one of the most important risk factors for type 2 diabetes and
the burden of the disease is very high in older age groups. In addition, older
people are more likely to have diabetes [40]. We see consistent results as far as
the distribution of diabetes over age. As a matter of fact, among adults in the
USA aged 65 or older, the prevalence of diagnosed diabetes in 2011 was 20%, or
more than eight times higher than the prevalence among adults 18 to 44 years
of age (2.4% prevalence) [40].
Obesity is known as a chronic low-grade inflammatory disorder that results a
triggering factor for many other metabolic and inflammatory disturbances [41].
Nearly 20.54% (71,466/347,869) with obesity have diabetes that is significantly
higher than the normal group, with a percent of 10.07 % (204,640/2,031,206).
The feature named ‘Cardiovascular’ is of interest that needs to be clarified.
In Mexico data, this identifies if the patient has a diagnosis of cardiovascular
disease. In California dataset, it prescribes to ‘coronary heart disease’. How-
ever, the California dataset doesn’t show significant difference, while the Mexico
data show that the proportion of cardiovascular diseases of positive cases are
greater than the proportion of cardiovascular diseases of negative cases (p-value
< 0.001). CDC has mentioned on their website presence of significant evidence
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Table 11. Summary table for two sample proportion tests for seven categorical vari-
ables in the Mexico data. We test the difference of two proportions for each variable
between positive and negative COVID-19 test groups. P-value, 95% confidence interval,
and conclusion for each variable are shown. * denotes significant variables (all variables
are significant).
Variable P-value 95% CI Conclusion at α = 0.05
With 95% confidence, the
proportion of
diabetes < 0.0001 * [0.0572, 1.0000] diabetes of positive cases is
greater than the proportion of
diabetes of negative cases.
Cardiovascular < 0.0001 * [0.0009, 1.0000] cardiovascular diseases of
positive cases are greater than
the proportion of cardiovascular
diseases of negative cases.
htn < 0.0001 * [0.0587, 1.0000] hypertension of positive cases is
greater than the proportion of
hypertension of negative cases.
smoke < 0.0001 * [-1.0000, -0.0165] smokers of positive cases is
smaller than the proportion of
smokers of negative cases.
asthma < 0.0001 * [-1.0000, -0.0047] asthma of positive cases is
smaller than the proportion of
asthma of negative cases.
copd < 0.0001 * [0.0021,1.0000] chronic obstructive pulmonary
disease of positive cases is
greater than the proportion of
chronic obstructive pulmonary
disease of negative cases.
Immunosuppression < 0.0001 * [-1.0000, -0.0021] immunosuppression of positive
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that coronary heart disease is an essential risk factor. The Mexico Data obtained
for this study did provide similar evidence to support this claim.
Among all the patients with asthma, nearly 3.05% (33,850/1,110,937) of neg-
ative cases have asthma, which is slightly higher than 2.54% (22,660/891,550)
in the positive group (p-value < 0.001). This is consistent with our previous
conclusion in California dataset; however, CDC asserts that asthma might be
at an increased risk for COVID-19, which seems contradictory. CDC highlights
the assumption “moderate-to-severe” of asthma as an increased relative risk for
COVID-19 that the “mild” asthma group may be excluded from consideration.
However, most of cases in California dataset are mild symptoms and asymp-
tomatic patients. Besides, we may need to add other factors such as immuno-
suppression to investigate such relationship.
Table 12. Contingency table and Chi-squared test for immunosuppression and
COVID-19 test results in the Mexico data are presented to determine whether there






Not Detected 879,472 1,093,540
Pearson’s Chi-squared Test
X-squared = 225.93 df =1 p-value < 0.0001
Conclusion: At the 0.01 significance level, there
is sufficient evidence that immunosuppression and
COVID-19 test results are not independent.
We briefly address relationship of immunosuppression as a pre-existing condi-
tion to COVID-19. In this dataset, there is an essential variable called immuno-
suppression (having a weakened immune system). Immunocompromised patients
have a reduced ability to fight infections and other diseases. If we relate immuno-
suppression with the COVID-19 test results, nearly 1.28% (14,186/1,110,937) of
negative cases have immunosuppression, which is relatively higher than 1.05%
(9,329/891,550) for the positive group. It seems to show that immunosuppres-
sion may not directly contribute to determine COVID-19 diagnostic testing.
However, based on the Chi-squared test in table 12, at the 0.01 significance
level, there is a statistical association between immunosuppression and COVID-
19 testing (p-value < 0.0001). Furthermore, in relation of immunosuppression
with diabetes, nearly 25.99% (7,064/27,182) of immunosuppression group have
diabetes, which is a significantly higher than 11.44% (269,000/2,351,286) for the
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non-immunosuppression group (p-value < 0.0001). It is important to note that
since the immune system is compromised, it is harder to fight the virus and
likely lead to a longer recovery period. Thus, the virus may thrive in an environ-
ment of elevated blood glucose, which leading to the illness of diabetes. Similarly,
when we detect the relationship between immunosuppression and asthma, nearly
5.73% (1,558/27,182) of immunosuppression group have asthma, which is a sig-
nificantly higher than 2.75% (64,653/2,351,286) for the non-immunosuppression
group (p-value < 0.0001). Taking medication for asthma may also weaken the
immune system, increasing the risk of developing other diseases which finally
may increase the probability of COVID-19 infection.
A recent discovery conducted by genome-wide association (GWAS) argued
that genes are associated with severe COVID-19 that two stretches of DNA,
which determine the blood type and support the immune system, are considered
as harboring risks for coronavirus. According to their findings, people with blood
type A face a 50% greater risk of needing oxygen support or a ventilator after
they were infected with COVID-19. Conversely, people with blood type O seems
to have about a 50 percent reduced risk of severe COVID-19 [42]. Moreover,
in 2016, evidence in a research paper has been presented that blood type B
is associated with high incidence of type 2 diabetes and blood group O has
minimum association with type 2 diabetes. Blood group A and AB were almost
equally distributed among diabetic and non-diabetic population [43].
5.3 Brazil Data
Table 13 includes the test accuracy results for the four different models. These
four models were used to predict/estimate whether a patient will be tested as
COVID-19 positive or negative based on relevant blood panel features. Thus,
four classification models presented the test accuracy to show its prediction
precision. Random forest performed the best among four considered algorithms
with a test accuracy of 0.9487 (AUC=0.9722). Table 14 describes test accu-
racy, Kappa statistics, sensitivity and specificity for the random forest model.
Leukocytes, platelets, eosinophils, C-reactive protein (protenia.C), monocytes,
and age are the most important factors that influence the final COVID-19 test
results (shown in figure 5). Platelets, leukocytes, eosinophils, age, red blood cells
(Red.Blood.Cells), monocytes, and C-reactive protein also turn out to be sig-
nificant in logistic regression model. In this dataset, all original numeric data
were standardized to have a mean of zero and a standard deviation of 1, we may
interpret some variables such as platelets, leukocytes and monocytes.
Finally we present the findings of using XGBoost to analyze the dataset.
SHAP which stands for SHapley Additive exPlanations [44] is utilized to reverse-
engineer the output of XGBoost. Given the good performance of XGBoost, we
can employ the SHAP technique to explain the impact of each feature, either
positively or negatively, to the response variable. The Summary plot in figure 6
presents all SHAP values for each feature in the x-axis direction. Feature values
are expressed as color gradients. The importance feature of the model is shown
on the y-axis in a descending order from top to bottom. That is, the top feature
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Table 13. Prediction accuracy of each machine learning method applied in the Brazil
data.





Fig. 5. Random forest feature importance and ROC curve of Brazil data. Charts cre-
ated in R.
is the most important and the bottom is the least important feature. From the
XGBoost summary plot, figure 6 (only shown the top-10 variable importance),
results for the variable importance are similar as results in the random forest
model. Moreover, we can see that low values of leukocytes and platelets are
indicators of COVID-19 presence, and high values of C-reactive protein and age
are strong indicator of COVID-19 presence.
In summary, all three models above agree that leukocytes, platelets, and
eosinophils, age and C-reactive protein are essential features which are associ-
ated with COVID-19 test results. Patients with low values of the leukocytes and
platelets, high values of C-reactive protein, and/or age are more likely to be diag-
nosed as COVID-19 positive. These assertions are comparable with a study with
116 confirmed Chinese patients in February, 2020, that “Patients with COVID-
19 have lower counts of leucocytes, lymphocytes, eosinophils, platelets, and
hemoglobin, but have higher neutrophil-lymphocyte ratio (NLR) and monocyte-
lymphocyte ratio (MLR), which were compared with controls (P < 0.001).” [45]
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Fig. 6. SHAP summary plot for XGBoost model. Chart created in R.
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Basically, the phenomenon of having a low counts of leukocytes is consistent
with recent statistics that leukopenia (decrease in the number of leukocytes) was
more common among severe COVID-19 patients, “COVID-19 presents in the
majority of cases with a rapidly progressive course of fever, cough and dyspnea
(shortness of breath). Important distinguishing factors are leukopenia and the
rapid progression to acute respiratory distress syndrome (ARDS).” [46]
According to a recent study, researchers in China analyzed 1099 patients from
31 provinces in China showed that “SARS-CoV-2 may reduce platelet produc-
tion that similarly inhibits hematopoiesis in the bone marrow through certain
receptors to cause decreased primary platelet formation and lead to thrombocy-
topenia. SARS-CoV-2 infection may increase platelet destruction that COVID-
19 may increase levels of autoantibodies and immune complexes, resulting in
specific destruction of platelets by the immune system.” [47]
C-reactive protein (CRP) is also an important feature to detect the presence
of COVID-19. Evidence in a recent research paper has been shown that“CRP
increased significantly in the severe COVID-19 group at the early stage. CRP
could be used to early identify patients who might become severely ill and before
the CT finding.” [48]
The death rate from coronavirus is much higher in the elderly than younger
adults. We define that age is an ‘Irreversible’ feature which means that age is
an irresistible objective factor that elder people will be inevitably more likely
to contract diseases compared with young people due to gradually weakened
immune system and metabolism.
6 Discussion
As mentioned above, most data have not been designed/engineered and collected
through a disciplined approach. Still unknown are measurement system issues in
that method, collection, process variations that are not assessed properly as well
as the cases of false negatives. It is now known that temperature is not a perfect
indicator for having COVID-19. In addition, it is not clear how the temperatures
of patients are taken of four common ways. This only adds to variation in data
further. In addition to this variation, there is operator to operator and within
variation of thermometer. None of this has been accounted for in data collec-
tion as well as analysis. There is also different classification of diabetes. Most
commonly three types of diabetes (type 1, type 2 and gestational) are used for
classification. However, it is not designed, nor specified in the datasets what type
of diabetes that patient has. Similarly, severity of asthma is not specified.
Despite all advancement in technology and data science in recent years, there
have been very chaotic approach to how to handle this pandemic from the medi-
cal field across the world. The pandemic has been highly politicized. The govern-
ments that have been afraid of economic collapse swayed the scientific process
to mislead the public and health organizations as they control the funding and
coordinating organizations. As we outlined above, even the very basic, yet mis-
leading reports have been produced. Some scientists, most of whom are trained
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medical doctors have come out with highly disagreeable and misleading state-
ments about the danger of this virus. Mostly, one factor at a time kind approach
instead of scientifically designed studies and approaches may have contributed
to millions to get infected (some with irreparable consequences) while more than
a million people worldwide losing their lives.
Potential improvements for the entire pandemic process are overwhelming
from first alerts to how to monitor, develop testing, containment to keeping the
entire process in check. Statisticians and other scientists must play an essential
role in future phenomenon. The world needs a cultural change in that most of the
problems we face are due to lack of designed data and turning them into good
information. Making an inference amid uncertainties requires being specialized
in statistics. All medical professionals, especially infectious disease specialists
should be trained enough in critical thinking and statistics to realize the value
that advanced statistics brings to the table. Hence, the inclusion of statisticians
along with other scientists and technical personnel become essential. In this
case, COVID-19 disaster is not only the failure of scientific community, but
it is a much bigger failure of worldwide systems. The world specifically needs
to implant statisticians, data scientists, engineers, process experts and other
medical personnel who understand the subtleties of the science of statistics to
stop the next pandemic in its tracks if not COVID-19.
Besides of all the points made in this paper, dietary support for people with
diabetes and other pre-existing conditions cannot be emphasized enough. Un-
fortunately in the early days of the pandemic, especially junk food items such
as potato chips and pizza in addition to immune depressant alcohol were the
most sold products with empty shelves of the US grocery stores. These are some
of the confounding features that could be studied through the contact tracing
and grocery store data. However, it is out of scope of this paper. As it has been
well established in the literature, the relationship of obesity to diabetes and
other diseases, this created a confounded variable that has not been studied well
among COVID-19 infected patients. A dietary guidelines supporting specifically
healthy immune system with attention to blood health (Platelets, leukocytes,
eosinophils, age, red blood cells (Red.Blood.Cells), monocytes, and C-reactive
protein) could have helped with severely COVID-19 ill patients if not most. For
instance, foods to increase blood platelets include vitamin K rich foods. This nu-
trient is necessary to ensure a healthy growth of cells at an optimum level in the
body. Eating dark green vegetables (kale, spinach), eggs, healthy cooked meats,
cabbage, parsley, et al will help increase your blood platelet count whether it is
related to diabetes or not [49].
Healthy nutrition is an essential component of any disease especially diabetes
management. It is therefore important for all people with diabetes to eat a color-
ful and balanced diet to keep their blood glucose levels stable and enhance their
immune system. It is utmost important for such people to take precautions that
includes dietary guidelines to avoid severe case of the virus. In addition to the
guidelines provided by CDC, cleanliness and social distancing are undoubtedly
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important for all and people living with diabetes and anyone in close contact
with people living with diabetes [20].
7 Conclusions
It is our hope that the extensive literature scan done here, by no means complete
is useful for diagnosing COVID-19 considering possible false negatives and even
perhaps how to treat it with the help of a complete blood panel. As of October
2020, there is no reliable anti-body testing or secondary testing of the infection
in case it is not present in upper respiratory system. Medical professionals can
use the help of blood work to further their understanding. In an ideal world,
humanity would have a process perfected at this point for the next pandemic.
There are many issues relating to the pandemic need to be studied. Simple
indicative measures could be used to understand the process of infection where
such measurements were obtained from smart devices.
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